Colorado State University spin-out VetDC acquires new drugs to tackle cancer in pets.

VetDC, a veterinarian biotech spin-out of Colorado State University (CSU), has acquired anti-cancer drugs from life sciences firm Pathway Therapeutics.

The firm aims to redevelop the drugs, originally designed to fight cancer in humans, to be useful to tackling tumours in animals. The drug, renamed VDC-597, blocks cancer cells from multiplying and growing in an animal’s body.

VetDC operates as a virtual company in order to keep operational and staffing costs down. It maintains a healthy relationship with CSU, which…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?